NICM
XLRN

Neo Ivy Capital Management’s Acceleron Pharma XLRN Stock Holding History

Neo Ivy Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,535
Closed -$432K – 674
2021
Q3 		$432K Buy
+4,535
New +$593K 0.5% 70
2020
Q3 		– Sell
-4,535
Closed -$432K – 660
2020
Q2 		$432K Buy
+4,535
New +$437K 0.5% 70

Neo Ivy Capital Management's XLRN Position: Q4 2021 in Review

Neo Ivy Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 4,535 shares — an estimated $432K sold.

Neo Ivy Capital Management first reported a position in XLRN in Q2 2020 and held it in 2 quarters. The position peaked at $432K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Neo Ivy Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 4,535 Acceleron Pharma shares in Q4 2021, an estimated $432K.
  • Neo Ivy Capital Management first reported a position in Acceleron Pharma in Q2 2020 and held it in 2 quarters.
  • Neo Ivy Capital Management's Acceleron Pharma position peaked at $432K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Neo Ivy Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.